Biocon Biologics Gets USFDA Approval for Cancer Biosimilar Jobevne

Published • 10 April 2025 at 3:03 PM

Jobevne biosimilar approved by USFDA for cancer treatment by Biocon Biologics.
Biocon Biologics receives USFDA approval for Jobevne, a biosimilar for cancer treatment.
Zee Business

Biocon Biologics, a subsidiary of Biocon Ltd, has received approval from the US Food and Drug Administration (USFDA) to market Jobevne (bevacizumab-nwgd), a biosimilar to the cancer drug Avastin. Jobevne, a recombinant humanised monoclonal antibody, is used to treat various types of cancer by inhibiting vascular endothelial growth factor (VEGF) and preventing angiogenesis, which limits tumor growth. This approval marks a significant achievement for Biocon Biologics, as Jobevne becomes their seventh biosimilar approved in the US. The company already markets the drug under the brand name Abeymy in Europe and Canada. Biocon Biologics’ CEO, Shreehas Tambe, emphasized that this approval reinforces the company’s commitment to providing high-quality, affordable cancer treatments, enhancing access to oncology care globally.

Key Highlights
  • Biocon Biologics receives USFDA approval for Jobevne (bevacizumab-nwgd).
  • Jobevne is a biosimilar to the cancer drug Avastin.
  • The drug is a recombinant humanized monoclonal antibody used in cancer treatment.
  • Jobevne inhibits vascular endothelial growth factor (VEGF) to limit tumor growth by preventing angiogenesis.
  • It marks Biocon Biologics’ seventh biosimilar approval in the US.
  • The drug is already marketed as Abeymy in Europe and Canada.
  • CEO Shreehas Tambe highlights the company's commitment to providing affordable, high-quality cancer treatments.
  • The approval strengthens Biocon Biologics' oncology portfolio and enhances global access to cancer care.

Latest News

BPSL faces liquidation after ₹19,700 crore bid by JSW Steel deemed illegal by court

SC Orders Liquidation of Bhushan Power, Rejects JSW Steel Plan as Illegal

Published • 2 May 2025 at 7:26 AM
Reliance Power inks ₹10,000 crore deal for 930 MW solar and 1,860 MWh BESS with SECI

Reliance NU Suntech Signs ₹10,000 Crore PPA for 930 MW Solar Power

Published • 2 May 2025 at 5:44 AM
Brunson’s clutch buzzer-beater seals series and sparks iconic “double bang” from Mike Breen.

Jalen Brunson's Clutch Shot Sends Knicks to Victory; Iconic "Double Bang!"

Published • 2 May 2025 at 4:57 AM
Amazon exceeds Q1 earnings estimates but lowers Q2 guidance, citing tariffs and trade concerns.

Amazon Q1 Earnings Beat, But Soft Q2 Guidance Amid Tariff Concerns

Published • 1 May 2025 at 10:52 PM
Reddit shares soar 20% after Q1 earnings beat, revenue hits $392M with 108M daily users.

Reddit Crushes Q1 Expectations: Shares Soar 20% on Earnings

Published • 1 May 2025 at 10:37 PM
Ford April sales increase 16% with strong truck demand, but EV sales decline 40%.

Ford U.S. Sales Rise 16% in April Despite 40% EV Sales Drop

Published • 1 May 2025 at 3:26 PM
GM lowers 2025 profit forecast amid $5B tariff impact; ramps up U.S. production efforts.

GM Cuts 2025 Profit Outlook by $4B-$5B Due to US Tariffs

Published • 1 May 2025 at 3:03 PM
Barclays posts £2.7B Q1 profit, boosted by 21% rise in fixed income trading revenue.

Barclays Q1 Profit Soars 19% to £2.7B, Beats Expectations

Published • 30 April 2025 at 7:23 AM
IndusInd Bank stock gains 3% as Deputy CEO Arun Khurana resigns citing trading issues.

IndusInd Bank Deputy CEO Resigns on Loss; Stock Shows Resilience

Published • 29 April 2025 at 4:51 AM
IBM commits $150 billion for U.S. manufacturing push, focusing on quantum computing growth.

IBM to Invest $150B in US, Boost Quantum & Mainframe Production

Published • 28 April 2025 at 4:27 PM
Wells Fargo advances toward lifting $1.95 trillion asset cap after consent order termination.

Wells Fargo Clears Another Hurdle, Nears End of Consent Orders

Published • 28 April 2025 at 2:05 PM
Adani Ports to acquire North Queensland Export Terminal for $2.54B in global expansion move

Adani Ports to Acquire Australian Export Terminal for $2.54 Billion

Published • 18 April 2025 at 12:54 PM